TY - JOUR
T1 - Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary
T2 - Results From Two Large Population-Based Case-Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data
AU - van Staa, Tjeerd Pieter
AU - Pirmohamed, Munir
AU - Sharma, Anita
AU - Buchan, Iain
AU - Ashcroft, Darren M.
N1 - Funding Information:
This study was supported by funding from the National Institute for Health and Care Research (Cluster randomized trial to improve antibiotic prescribing in primary care: individualized knowledge support during consultation for general practitioners and patients: Grant number NIHR130581) and Health Data Research UK (Better Care Northern Partnership, Better antibiotic prescribing in frail elderly people with polypharmacy: learning from practice and nudging prescribers into better practices BetterRx). DMA is funded by the National Institute for Health and Care Research through the Greater Manchester Patient Safety Translational Research Centre (NIHR Greater Manchester PSTRC, Grant number: PSTRC-2016-003). IB is funded by NIHR NW Coast Applied Research Collaboration. This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency (MHRA). The data are provided by patients and collected by the NHS as part of their care and support. Hospital Episode Statistics data are subject to Crown copyright (2022) protection, reused with the permission of The Health & Social Care Information Centre, all rights reserved. The interpretation and conclusions contained in this study are those of the authors alone, and not necessarily those of the MHRA, NIHR, NHS, or the Department of Health and Social Care. The study protocol was approved by CPRD's Independent Scientific Advisory Committee (ISAC) (reference: 20_150R). CPRD has ethics approval from the Health Research Authority to support research using anonymized patient data (https://cprd.com/safeguarding-patient-data). We would like to acknowledge all the data providers and general practices who make anonymized data available for research. The study data cannot be shared due information governance and licensing rules. However, researchers can submit research protocols to ISAC and conduct analyses independently after obtaining research protocol approval and signing the data license. Dissemination to participants and related patient and public communities: We used anonymized data and, therefore, did not have direct contact information for individual study participants for dissemination of the results.
Funding Information:
This study was supported by funding from the National Institute for Health and Care Research (Cluster randomized trial to improve antibiotic prescribing in primary care: individualized knowledge support during consultation for general practitioners and patients: Grant number NIHR130581) and Health Data Research UK (Better Care Northern Partnership, Better antibiotic prescribing in frail elderly people with polypharmacy: learning from practice and nudging prescribers into better practices BetterRx). DMA is funded by the National Institute for Health and Care Research through the Greater Manchester Patient Safety Translational Research Centre (NIHR Greater Manchester PSTRC, Grant number: PSTRC‐2016‐003). IB is funded by NIHR NW Coast Applied Research Collaboration.
Publisher Copyright:
© 2022 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2023/1/24
Y1 - 2023/1/24
N2 - This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding. Data sources were Clinical Practice Research Databank GOLD and Aurum anonymized electronic health records from English general practices linked to hospital admission records. In propensity-matched case-control study, outcomes were ADR or emergency admissions. Analyzed were 121,546 ADR-related admission cases matched to 638,238 controls. For most antibiotics, adjusted odds ratios (aORs) for ADR-related hospital admission were large (aOR for trimethoprim 4.13; 95% confidence interval (CI), 3.97–4.30). Of the 51 DDIs evaluated for ADR-related admissions, 38 DDIs (74.5%) had statistically increased aORs of concomitant exposure compared with nonexposure (mean aOR 3.96; range 1.59–11.42); for the 89 DDIs for emergency hospital admission, the results were 75 (84.3%) and mean aOR 2.40; range 1.43–4.17. Changing reference group to single antibiotic exposure reduced aORs for concomitant exposure by 76.5% and 83.0%, respectively. Medicines listed to cause nephrotoxicity substantially increased risks that were related to number of medicines (aOR was 2.55 (95% CI, 2.46–2.64) for current use of 1 and 10.44 (95% CI, 7.36–14.81) for 3 or more medicines). In conclusion, no evidence of substantial risk was found for multiple DDIs with antibiotics despite warnings of severe outcomes in a national formulary and flagging in electronic health record software. It is proposed that the evidence base for inclusion of DDIs in national formularies be strengthened and made publicly accessible and indiscriminate flagging, which compounds alert fatigue, be reduced.
AB - This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding. Data sources were Clinical Practice Research Databank GOLD and Aurum anonymized electronic health records from English general practices linked to hospital admission records. In propensity-matched case-control study, outcomes were ADR or emergency admissions. Analyzed were 121,546 ADR-related admission cases matched to 638,238 controls. For most antibiotics, adjusted odds ratios (aORs) for ADR-related hospital admission were large (aOR for trimethoprim 4.13; 95% confidence interval (CI), 3.97–4.30). Of the 51 DDIs evaluated for ADR-related admissions, 38 DDIs (74.5%) had statistically increased aORs of concomitant exposure compared with nonexposure (mean aOR 3.96; range 1.59–11.42); for the 89 DDIs for emergency hospital admission, the results were 75 (84.3%) and mean aOR 2.40; range 1.43–4.17. Changing reference group to single antibiotic exposure reduced aORs for concomitant exposure by 76.5% and 83.0%, respectively. Medicines listed to cause nephrotoxicity substantially increased risks that were related to number of medicines (aOR was 2.55 (95% CI, 2.46–2.64) for current use of 1 and 10.44 (95% CI, 7.36–14.81) for 3 or more medicines). In conclusion, no evidence of substantial risk was found for multiple DDIs with antibiotics despite warnings of severe outcomes in a national formulary and flagging in electronic health record software. It is proposed that the evidence base for inclusion of DDIs in national formularies be strengthened and made publicly accessible and indiscriminate flagging, which compounds alert fatigue, be reduced.
U2 - 10.1002/cpt.2807
DO - 10.1002/cpt.2807
M3 - Article
C2 - 36448824
AN - SCOPUS:85144033676
SN - 0009-9236
VL - 113
SP - 423
EP - 434
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 2
ER -